BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OncoC4\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies OncoC4\, Inc.'s drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05682443-2413@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Gotistobart: Phase 1/2 readout est. (NCT05682443)
DESCRIPTION:Gotistobart\, phase 1/2.\nStudy: ONC-392 Plus Lutetium Lu 177 V
 ipivotide Tetraxetan in Patients With mCRPC\nEstimated primary completion:
  30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/go
 tistobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05682443
URL:https://assetmemo.bio/drug/gotistobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-2413@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gotistobart: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Gotistobart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of An
 ti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/got
 istobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04140526
URL:https://assetmemo.bio/drug/gotistobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671510-2413@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Gotistobart: Phase 3 readout est. (NCT05671510)
DESCRIPTION:Gotistobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ONC
 -392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 In
 hibitors\nEstimated primary completion: 31 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gotistobart#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05671510
URL:https://assetmemo.bio/drug/gotistobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659379-2413@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20360701
DTEND;VALUE=DATE:20360702
SUMMARY:Gotistobart: Phase 3 readout est. (NCT07659379)
DESCRIPTION:Gotistobart\, phase 3.\nStudy: Gotistobart Long Term Extension 
 (LTE) Study\nEstimated primary completion: 1 July 2036. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gotistobart#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07659379
URL:https://assetmemo.bio/drug/gotistobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
